BRIEF-Rvl Pharmaceuticals Plc Announces Preliminary Q4 Sequential Growth Of 21%

Reuters
09 Jan 2023

Jan 9 (Reuters) - RVL Pharmaceuticals PLC :

* RVL PHARMACEUTICALS PLC ANNOUNCES PRELIMINARY FOURTH QUARTER SEQUENTIAL GROWTH OF 21% AND FULL YEAR 2022 UPNEEQ® NET PRODUCT SALES

* RVL PHARMACEUTICALS PLC - EXPECTS Q4 2022 PRELIMINARY UPNEEQ NET PRODUCT SALES OF APPROXIMATELY $12.1 MILLION, REPRESENTING AN INCREASE OF 21% OVER Q3 2022

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10